RHÖN-KLINIKUM AG

  • WKN: 704230
  • ISIN: DE0007042301
  • Land: Deutschland

Nachricht vom 11.03.2019 | 16:30

RHÖN-KLINIKUM AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

RHÖN-KLINIKUM AG

11.03.2019 / 16:30
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Name: RHÖN-KLINIKUM AG
Street: Salzburger Leite 1
Postal code: 97616
City: Bad Neustadt a.d.Saale
Germany
Legal Entity Identifier (LEI): 529900MVGMIVUDQY9E20

2. Reason for notification
X Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
X Other reason:
Voluntary group communication only at subsidiary level

3. Details of person subject to the notification obligation
Natural person (first name, surname): Ludwig Georg Prof. Dr. h.c. Braun
Date of birth: 21 Sep 1943

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
B. Braun Melsungen AG

5. Date on which threshold was crossed or reached:
03 Sep 2018

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 25.23 % 0.00 % 25.23 % 66,962,470
Previous notification 25.0003 % % 25.0003 % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE0007042301 16895625 % 25.23 %
Total 16895625 25.23 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
%
    Total %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
%
      Total %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
Prof. Dr. h.c. Ludwig Georg Braun % % %
Ludwig G. Braun GmbH & Co. KG % % %
B. Braun Holding GmbH & Co. KG % % %
B. Braun Familienholding Verwaltungs SE % % %
B. Braun Familienholding SE & Co. KG % % %
B. Braun Melsungen Aktiengesellschaft 25.23 % % 25.23 %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
 

Date
08 March 2019



11.03.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

MBH Corporation. Hohes Kurspotenzial

Die MBH Corporation plc hat in den vergangenen Berichtsperioden eine sehr hohe M&A-Aktivität aufgezeigt. Unter Anwendung der so genannten Agglomeration Methodology hat die Beteiligungsgesellschaft branchenübergreifend seit 2018 11 Beteiligungen erworben. Bei einem Pro-Forma-Umsatz der Beteiligungsgesellschaften von über 120 Mio. GBP und einem Pro-Forma-EBITDA in Höhe von über 11 Mio. GBP weist die MBH derzeit eine Marktkapitalisierung von umgerechnet gerade einmal 19,8 Mio. GBP auf. Ausgehend vom aktuellen Aktienkurs liegt zu unserem Kursziel in Höhe von 1,95 € ein hohes Kurspotenzial vor

News im Fokus

Fresenius Medical Care kooperiert mit anderen Dialyseanbietern zur Bekämpfung der Coronavirus-Pandemie in den USA

01. April 2020, 09:01

Aktueller Webcast

SeaChange Corporation

Fourth Quarter Fiscal Year 2020 Results

06. April 2020

Aktuelle Research-Studie

Original-Research: Valneva SA (von First Berlin Equity Research GmbH): Kaufen Valneva SA

02. April 2020